Role of RUNX2 in Oral Squamous Cell Carcinoma (OSCC): A Systematic Scoping Review

AL-Hamad, Khalid A.

doi:https://doi.org/10.1155/2024/4775320

European Journal of Cancer Care

On this page

Abstract Introduction Results and Discussion Conclusion Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2024 | Article ID 4775320 | https://doi.org/10.1155/2024/4775320

Role of RUNX2 in Oral Squamous Cell Carcinoma (OSCC): A Systematic Scoping Review

Khalid A. AL-Hamad¹

Academic Editor: Nemat Ali

Received19 Oct 2023

Revised24 Dec 2023

Accepted24 Feb 2024

Published07 Mar 2024

Abstract

RUNX2, known as the core-binding factor subunit alpha-1 (Cbfa1), is a protein-coding gene recognized and responsible for its involvement in bone development and osteoblast differentiation. However, its dysregulation and aberrant expression have been linked to the pathogenesis of many diseases, such as oral squamous cell carcinoma (OSCC). This review highlights the significance of the RUNX2 gene in oral squamous cell carcinoma. Objectives. To review the contribution of the RUNX2 gene in oral squamous cell carcinoma and its implication on clinical diagnosis and treatments. Materials and Methods. A systematic scoping review was conducted to elucidate the role of RUNX2 in OSCC. A framework of five stages for scoping reviews outlined by Arksey and O’Malley (2005) was adopted for the current study. Results. The review showed that RUNX2 plays a role in the development and progression of OSCC, a common form of head and neck cancer. Conclusion. RUNX2 is an essential player in the molecular mechanisms underlying the development and progression of oral squamous cell carcinoma, and its dysregulation promotes tumor initiation, progression, and metastasis, making it a potential target therapy for future research aimed at developing novel therapies for oral squamous cell carcinoma. Clinical Relevance. Understanding the precise mechanisms by which RUNX2 contributes to OSCC pathogenesis can lead to target treatment for this challenging form of cancer.

1. Introduction

RUNX2, known as core binding factor alpha 1subunit (Cbfa1), Pebp2αA is a member of the RUNX family of transcription factors, which are characterized by their DNA-binding domains, known as the Runt domains [1]. RUNX2 is a transcription factor protein that is essential for bone formation and is known to play an important role in various other biological processes [2].

In bone formation, RUNX2 is a master regulator of osteoblast differentiation and bone formation. It has been shown to be essential for the responsibility of mesenchymal stem cells to the osteoblast lineage, as well as for the differentiation of preosteoblasts into mature osteoblasts [3]. RUNX2 is also involved in the mineralization of bone matrix and the regulation of bone remodeling (Figure 1) [3, 4]. RUNX2 is also involved in other biological processes, including the regulation of tooth development, chondrogenesis, and the maintenance of the hematopoietic stem cell [5, 6]. In addition, it has been shown to play a role in the regulation of angiogenesis and tumor metastasis [7].

Osteoblasts produce and mineralize the extracellular matrix of bone, essential for maintaining skeletal integrity. RUNX2 activates the expression of various genes involved in osteoblast differentiation, including alkaline phosphatase (ALP), osteocalcin (OCN), and collagen type I (COL1A1) [8]. Furthermore, RUNX2 is also involved in maintaining bone homeostasis and remodeling by regulating osteoclast differentiation and activity [9]. RUNX2 is also implicated in chondrogenesis, the process by which cartilage is formed. In chondrocytes, RUNX2 plays a role in regulating the expression of genes involved in chondrocyte differentiation, such as type II collagen (COL2A1) and aggrecan (ACAN) [10, 11]. Additionally, RUNX2 is involved in developing craniofacial bones and teeth [12].

RUNX2 is a critical factor in bone formation and other biological processes, and its dysregulation has been implicated in a variety of skeletal and nonskeletal diseases [13]. For example, mutations in the RUNX2 gene have been associated with cleidocranial dysplasia, a skeletal disorder characterized by abnormal bone development [14]. RUNX2 has also been implicated in developing and progressing breast and prostate cancer [15, 16]. The function of RUNX2 is regulated by a variety of signaling pathways, including the Wnt, BMP, FGF, Shh, and PTH pathways [4], and RUNX2 activity is also modulated by posttranslational modifications, including phosphorylation, acetylation, and SUMOylation [17]. Runx2-dependent transcription is regulated by posttranslational modifications and interactions with additional nuclear factors. The key components involved in these modifications include chromatin remodelers such as the Swi/Snf complex [18], ATPase proteins Rvb1 and Rvb2 [19], and histone 3 lysine 9 (H3K9) demethylases like JMJD2d/Kdm4d [20]. The Swi/Snf complex is required for cotranscriptional nucleosome remodeling, leading to transcriptional interference and repression of gene expression [21]. Rvb1 and Rvb2 proteins are enriched at gene promoters and mRNAs, where they sequester mRNAs into mRNP granules and repress their translation [22]. JMJD2d/Kdm4d demethylase regulates type I interferon responses by affecting the transcription of enhancer RNAs (eRNAs) and dynamic H3K9me2 at associated promoters. These components play crucial roles in regulating Runx2-dependent transcription through various mechanisms, including chromatin remodeling, mRNA localization, and translatability. The main driving components that play a major role in dysregulation and aberrant expression of RUNX2 in cancer are several. One mechanism involves the cooperation of enhancers and chromatin looping, which is controlled by the transcription factor c-JUN and the epigenetic regulator BRD4 [23]. Another mechanism involves the activity of histone deacetylases (HDACs), particularly HDAC1 and HDAC6, which are required for efficient transcription of RUNX2 in cancer cells [24]. Additionally, constitutive activation of signaling pathways, such as ERK, Smads, cdks, and Akt, can lead to aberrant expression and activation of RUNX2 [24]. Treatment with histone deacetylase inhibitors (HDACi) can inhibit RUNX2 expression by disrupting the transcription-activating complex on the enhancer element within the RUNX2 gene [25]. These findings suggest that dysregulation and aberrant expression of RUNX2 in cancer can result from a combination of enhancer-mediated chromatin looping, epigenetic regulation by HDACs, and activation of signaling pathways. Recent studies have suggested that RUNX2 may also have a role in cancer. In particular, RUNX2 has been found to be overexpressed in various types of cancer, including breast, prostate, and lung cancer [15, 26, 27]. RUNX2 is thought to promote tumor growth and metastasis by inducing the expression of genes involved in angiogenesis, cell migration, and invasion. A study by Yang DP et al. (2020) found RUNX2 was overexpressed in lung squamous carcinoma and correlated with the clinical progression of this fatal disease [27].

Dysregulation and aberrant expression of RUNX2 have been linked to the pathogenesis of OSCC. Its dysregulation promotes tumor initiation, progression, and metastasis [28]. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally, and OSCC is the most common malignant type of HNSCC [29, 30]. Cancer is a leading cause of death globally, accounting for one in six deaths or nearly 10 million in 2020 [31]. With recent scientific advances in cancer detection and treatment, the survival rate of many cancer types has witnessed tremendous improvement. However, HNSCC has a poor survival rate with the 5-year survival rate at an abysmally low level of 50%. Recurrence and metastasis are the main reasons for the poor survival rate [32]. Recurrence occurs in about half of all HNSCC patients [33]. Hence, novel therapeutic strategies aimed at controlling recurrence and metastasis can go a long way in improving the prognosis and survival rate of the patients.

This review systematically identified evidence from the recent research studies on the role of RUNX2 in HNSCC. It explored the possibility that RUNX2 could be used as a biomarker for the prognosis of OSCC. The prevailing perception and scope of development of therapeutic strategies using RUNX2 to treat OSCC are emphasized.

2. Methodology

Before the advent of the current review, a preliminary search of MEDLINE, the Web of Science, and JBI Evidence Synthesis was conducted, and no current or ongoing systematic reviews or scoping reviews on the topic were identified. The current scoping review was conducted following the framework designed by Arksey and O’Malley following the 5-step framework [34].

2.1. Identifying the Research Question

(i)The main research question was “What is the role of RUNX2 in oral squamous cell carcinoma?” the subquestions were “What are the types of studies conducted on the role of RUNX2 in OSCC?” “Does RUNX2 have any prognostic or therapeutic role in OSCC?” and “What are the gaps in the literature available on this topic?”.(ii)Identifying relevant studies

Following the PCC (population, concept, and context) criteria, with the population being OSCC and HNSCC patients and the concept being the role of RUNX2, relevant studies were identified using specific eligibility criteria. Only original research articles published in peer-reviewed journals and in English language were considered for the review. Preprints were excluded. An elaborate scientific literature search was executed with no start date restriction until 8 September 2023 in the electronic databases MEDLINE, Web of Science, and Scopus, following specific eligibility criteria. The protocol for search terms and the search strategy used for MEDLINE and Web of Science is given in Tables 1–3, respectively.

2.1.1. Selection of Studies for Inclusion

The results of the search and the study inclusion process are presented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping review (PRISMA-ScR) flow diagram (Figure 2) [35]. After reading through the title and abstract of the articles, one article was excluded for being a meeting abstract, whose full text was not available online. After full-text screening was performed, two articles were excluded because they were not appropriate for the review. Finally, seven articles were included in this review. Following the search, all identified citations were collated and uploaded into EndNote version 21, and duplicates were removed. Titles and abstracts were screened for assessment against the inclusion criteria for the review. A total of 10 studies were selected by this method.

2.1.2. Data Extraction and Charting of Data

After a thorough reading of the selected articles, the required data were extracted and entered into MS word. The collected data included authors, date of publication, study type, study population, and key points to be taken from the study (Table 3). The data were regularly updated and meticulously charted.

2.1.3. Collating, Summarizing, and Reporting of Results

A thorough summary of the results was prepared, and a narrative approach is used to report the results of this systematic scoping review using figures and tables [34, 36].

3. Results and Discussion

The result of the review is given in Table 3. The role of RUNX2 in OSCC was thoroughly studied and summarized legibly in this review.

3.1. RUNX2 and OSCC

High RUNX2 expression levels have been observed in OSCC tissues and are associated with tumor growth, invasion, and metastasis. RUNX2 interacts with several signaling pathways involved in OSCC pathogenesis, such as the Hedgehog signaling pathway. Zhang et al. mentioned that RUNX2 promoted fibroblast activation and OSCC cell proliferation and migration [28]. It is a multipotent transcription factor that regulates various genes and interacts with different oncogenic transcription factors of HNSCC, like TP53, JUN, and HIF-1A [37–40].

RUNX2 plays a major role in tumor cells’ transformation, growth, metastasis, cachexia, and hypercalcemia [7, 41]. RUNX2 crosstalks with other transcription factors to regulate the function of oncogenes and cancer progression. It also has a prometastatic function, playing a significant role in the cervical metastasis in HNSCC [23]. In HNSCC, RUNX2 collaborates or engages in crosstalk with other transcription factors to regulate oncogenes’ functions and influence the progression of cancer [23]. Chang et al. found that in HNSCC, RUNX2 could have a specific transcription target and demonstrated the prometastatic function of RUNX2 [23].

Increased expression of RUNX2 following the knockdown of tumor suppressor microRNA, miRNA-376c-3p, leads to an upregulation of invasive and migratory abilities of tumor cells and increased infiltration of cervical lymph nodes [23] .

3.2. RUNX2 as a Prognostic Biomarker

RUNX2 has been linked to the development of metastasis in various cancers. In OSCC, its expression may be associated with an increased risk of lymph node metastasis [23]. Therefore, assessing RUNX2 levels could aid in predicting the likelihood of metastasis and tailoring treatment strategies accordingly.

Wen et al. identified RUNX2 as one of the most tumor-specific markers for hepatocellular carcinoma (HCC) [48]. The methylation levels of RUNX2 showed a strong positive correlation with tumor size and could differentiate between cancer patients and controls, enabling sensitive detection. RUNX2 was one of the markers that provided a more specific indication of HCC presence [48]. It is also an independent prognostic biomarker of gastric cancer, linked with the invasion and differentiation of gastric cancer [42].

MicroRNA miR-376c, which inhibits the metastasis of tumor cells in OSCC, suppresses RUNX2 expression [23]. High RUNX2 expression levels were linked with unfavorable prognosis in OSCC patients, indicating the potential use of RUNX2 as a prognostic biomarker. Several studies have shown that the expression levels of RUNX2 can be used to predict the likelihood of recurrence, metastasis, and survival in OSCC patients [45, 46]. However, further studies and investigations are needed to validate these findings and establish the clinical utility of RUNX2 as a prognostic biomarker.

RUNX2 mRNA and protein levels were found to be elevated in clinical HNSCC cases [45]. A study by Chang et al. showed RUNX2 to stimulate HNSCC via parathyroid hormone-like hormone (PTHLH) and was found to be a poor prognostic marker for HNSCC [45]. It was found that PTHLH, calcium, and RUNX2 form a positive feedback loop in HNSCC, and in HNSCC patients, the RUNX2-PTHLH axis promoted tumor growth [45]. Recent studies show that the most activated upstream regulator in highly metastatic HNSCC was RUNX2 [23, 49]. RUNX2 was found to promote the proliferation abilities of HNSCC cells in vitro and tumor growth in vivo [45].

MRE11 is crucial for DNA double-strand breaks and is the nuclease component of the RAD50/MRE11/NBS1 DNA repair complex. It is also found to be a critical factor in cancer development [50]. In OSCC, MRE11 expression was associated with increased tumor size, cancer stage, and lymph node metastasis. It also predicted poorer patient survival and radiotherapy resistance [43]. Wang et al. found that MRE11 enhanced tumor proliferation, migration, and invasion, which was mediated by RUNX2 CXCR4, AKT, and FOXA2 [43].

3.3. Targeting RUNX2 for OSCC Therapy

MicroRNAs have several translational uses, including being diagnostic and prognostic biomarkers. MicroRNA miR-23a was found to inhibit invasion, proliferation, and clonogenesis of OSCC cells by inhibiting RUNX2 regulation of the PTEN/PI3K/Akt signaling pathway [42]. Chang et al. suggested that therapeutic targeting of the transcriptional activity of RUNX2 by miR-376c treatment could combat the metastatic progression of HNSCC [23]. An experimental study by Ma et al. found that miR-23a-3p inhibits the malignant progression of OSCC [42].

RUNX2’s involvement in the progression of oral cancer makes it a potential therapeutic target. Inhibiting or modulating RUNX2 activity could be explored to suppress tumor growth and metastasis. Targeting RUNX2 may represent a promising therapeutic approach for OSCC treatment. Studies have shown that RUNX2 inhibition using siRNA or small molecule inhibitors suppresses OSCC cell growth, invasion, and metastasis in vitro and in vivo [23]. Moreover, RUNX2 inhibition has sensitized OSCC cells to chemotherapy and radiation therapy. However, more studies are needed to determine the safety and efficacy of RUNX2 inhibition as a therapeutic approach for OSCC.

4. Conclusion

RUNX2 is a critical transcription factor that plays a key role in bone formation and other biological processes. Various signaling pathways and posttranslational modifications tightly regulate its activity. Dysregulation of RUNX2 has been implicated in various skeletal and nonskeletal diseases. Recent studies have implicated RUNX2 in cancer, suggesting a potential therapeutic target for the treatment of cancer, including OSCC. They may serve as a prognostic biomarker and therapeutic target for OSCC treatment.

Elevated levels of RUNX2 expression have been detected in OSCC tissues and are correlated with the growth, invasion, and metastasis of tumors. RUNX2 has been associated with the development of metastasis across various cancers, and in the case of OSCC, its expression may be linked to an increased risk of lymph node metastasis. Consequently, evaluating the levels of RUNX2 could assist in predicting the likelihood of metastasis, guiding treatment strategies accordingly. Moreover, heightened RUNX2 expression has been associated with an unfavorable prognosis in OSCC patients, suggesting the potential utility of RUNX2 as a prognostic biomarker. Given RUNX2’s role in the progression of oral cancer, it emerges as a plausible therapeutic target. Exploring the inhibition or modulation of RUNX2 activity could be considered to suppress both tumor growth and metastasis. Therefore, targeting RUNX2 presents a promising therapeutic approach for the treatment of OSCC. There is a dearth of studies analyzing the molecular mechanisms involved in the role of RUNX2 in OSCC. Future studies should further elucidate the molecular mechanisms underlying RUNX2-mediated OSCC pathogenesis and develop safe and effective RUNX2-targeted therapies for OSCC patients.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The author declares that there are no conflicts of interest.

Authors’ Contributions

Khalid A. AL-Hamad performed writing of the manuscript and contributed to the main text.

Acknowledgments

The author extends the appreciation to the Deanship of Postgraduate Studies and Scientific Research at Majmaah University for funding this research work through the project number (R-2024-990).

References

K. Gomathi, N. Akshaya, N. Srinaath, A. Moorthi, and N. Selvamurugan, “Regulation of Runx2 by post-translational modifications in osteoblast differentiation,” Life Sciences, vol. 245, Article ID 117389, 2020.
View at: Publisher Site | Google Scholar
R. T. Franceschi, G. Xiao, D. Jiang, R. Gopalakrishnan, S. Yang, and E. Reith, “Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation,” Connective Tissue Research, vol. 44, no. 1, pp. 109–116, 2003.
View at: Publisher Site | Google Scholar
J. B. Lian and G. S. Stein, “Runx2/Cbfa1: a multifunctional regulator of bone formation,” Current Pharmaceutical Design, vol. 9, no. 32, pp. 2677–2685, 2003.
View at: Publisher Site | Google Scholar
W.-J. Kim, H.-L. Shin, B.-S. Kim, H.-J. Kim, and H.-M. Ryoo, “RUNX2-modifying enzymes: therapeutic targets for bone diseases,” Experimental and Molecular Medicine, vol. 52, no. 8, pp. 1178–1184, 2020.
View at: Publisher Site | Google Scholar
S. Camilleri and F. McDonald, “Runx2 and dental development,” European Journal of Oral Sciences, vol. 114, no. 5, pp. 361–373, 2006.
View at: Publisher Site | Google Scholar
W. Zhao, S. Zhang, B. Wang, J. Huang, W. W. Lu, and D. Chen, “Runx2 and microRNA regulation in bone and cartilage diseases,” Annals of the New York Academy of Sciences, vol. 1383, no. 1, pp. 80–87, 2016.
View at: Publisher Site | Google Scholar
J. Pratap, J. B. Lian, A. Javed et al., “Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone,” Cancer and Metastasis Reviews, vol. 25, no. 4, pp. 589–600, 2006.
View at: Publisher Site | Google Scholar
S. Chen, J. Gluhak-Heinrich, Y. H. Wang et al., “Runx2, osx, and dspp in tooth development,” Journal of Dental Research, vol. 88, no. 10, pp. 904–909, 2009.
View at: Publisher Site | Google Scholar
T. Komori, “Runx2, an inducer of osteoblast and chondrocyte differentiation,” Histochemistry and Cell Biology, vol. 149, no. 4, pp. 313–323, 2018.
View at: Publisher Site | Google Scholar
G. Karsenty, “Transcriptional control of skeletogenesis,” Annual Review of Genomics and Human Genetics, vol. 9, no. 1, pp. 183–196, 2008.
View at: Publisher Site | Google Scholar
G. Dobreva, M. Chahrour, M. Dautzenberg et al., “SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation,” Cell, vol. 125, no. 5, pp. 971–986, 2006.
View at: Publisher Site | Google Scholar
R. G. Anthony, R. Henriques, A. Helfer et al., “A protein kinase target of a PDK1 signalling pathway is involved in root hair growth in Arabidopsis,” European Molecular Biology Organization Journal, vol. 23, no. 3, pp. 572–581, 2004.
View at: Publisher Site | Google Scholar
P. Ducy, R. Zhang, V. Geoffroy, A. L. Ridall, and G. Karsenty, “Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation,” Cell, vol. 89, no. 5, pp. 747–754, 1997.
View at: Publisher Site | Google Scholar
T. Komori, H. Yagi, S. Nomura et al., “Targeted disruption of results in a complete lack of bone formation owing to maturational arrest of osteoblasts,” Cell, vol. 89, no. 5, pp. 755–764, 1997.
View at: Publisher Site | Google Scholar
W. Si, C. Kan, L. Zhang, and F. Li, “Role of RUNX2 in breast cancer development and drug resistance,” Oncology Letters, vol. 25, no. 5, pp. 1–11, 2023.
View at: Google Scholar
C. Ge, G. Zhao, Y. Li et al., “Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease,” Oncogene, vol. 35, no. 3, pp. 366–376, 2016.
View at: Publisher Site | Google Scholar
R. T. Franceschi and G. Xiao, “Regulation of the osteoblast‐specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways,” Journal of Cellular Biochemistry, vol. 88, no. 3, pp. 446–454, 2003.
View at: Publisher Site | Google Scholar
A. L. Thomas, J. Marsman, J. Antony, W. Schierding, J. M. O’Sullivan, and J. A. Horsfield, “Transcriptional regulation of RUNX1: an informatics analysis,” Genes, vol. 12, no. 8, p. 1175, 2021.
View at: Publisher Site | Google Scholar
Y. S. Chen, W. Hou, S. Tracy et al., “Rvb1/Rvb2 proteins couple transcription and translation during glucose starvation,” Elife, vol. 11, Article ID e76965, 2022.
View at: Publisher Site | Google Scholar
K. Morse, S. Swerdlow, and E. Ünal, “Swi/snf chromatin remodeling regulates transcriptional interference and gene repression,” bioRxiv, Article ID 538572, 2023.
View at: Publisher Site | Google Scholar
R. Chandwani, T. C. Fang, S. Dewell, and A. Tarakhovsky, “Control of enhancer and promoter activation in the type I interferon response by the histone demethylase Kdm4d/JMJD2d,” Frontiers in Immunology, vol. 14, Article ID 1146699, 2023.
View at: Publisher Site | Google Scholar
Q. Zhang, H. Zuo, S. Yu et al., “RUNX2 co‐operates with EGR1 to regulate osteogenic differentiation through Htra1 enhancers,” Journal of Cellular Physiology, vol. 235, no. 11, pp. 8601–8612, 2020.
View at: Publisher Site | Google Scholar
W. M. Chang, Y. F. Lin, C. Y. Su et al., “Dysregulation of RUNX2/activin-A axis upon miR-376c downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma,” Cancer Research, vol. 76, no. 24, pp. 7140–7150, 2016.
View at: Publisher Site | Google Scholar
V. Sancisi, G. Manzotti, M. Gugnoni et al., “RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN,” Nucleic Acids Research, vol. 45, no. 19, pp. 11249–11267, 2017.
View at: Publisher Site | Google Scholar
J. L. Brusgard and A. Passaniti, “RUNX2 transcriptional regulation in development and disease,” Nuclear Signaling Pathways and Targeting Transcription in Cancer, vol. 10, no. 12, pp. 57–86, 2014.
View at: Publisher Site | Google Scholar
X. Yin, X. Teng, T. Ma et al., “RUNX2 recruits the NuRD (MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis,” Cell Death & Differentiation, vol. 29, no. 11, pp. 2203–2217, 2022.
View at: Publisher Site | Google Scholar
D. P. Yang, H. P. Lu, G. Chen et al., “Integrated expression analysis revealed RUNX2 upregulation in lung squamous cell carcinoma tissues,” Institution of Engineering and Technology Systems Biology, vol. 14, no. 5, pp. 252–260, 2020.
View at: Publisher Site | Google Scholar
D. Zhang, Y. Song, D. Li et al., “Cancer-associated fibroblasts promote tumor progression by lncRNA-mediated RUNX2/GDF10 signaling in oral squamous cell carcinoma,” Molecular Oncology, vol. 16, no. 3, pp. 780–794, 2022.
View at: Publisher Site | Google Scholar
E. Pons-Fuster López, F. Gómez García, and P. López Jornet, “Combination of 5-Florouracil and polyphenol EGCG exerts suppressive effects on oral cancer cells exposed to radiation,” Archives of Oral Biology, vol. 101, pp. 8–12, 2019.
View at: Publisher Site | Google Scholar
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
View at: Publisher Site | Google Scholar
Who, Cancer, Who, Geneva, Switzerland, 2022.
C. R. Leemans, B. J. Braakhuis, and R. H. Brakenhoff, “The molecular biology of head and neck cancer,” Nature Reviews Cancer, vol. 11, no. 1, pp. 9–22, 2011.
View at: Publisher Site | Google Scholar
Z. Zhao, D. Li, Z. Wu, Q. Wang, Z. Ma, and C. Zhang, “Research progress and prospect of nanoplatforms for treatment of oral cancer,” Frontiers in Pharmacology, vol. 11, Article ID 616101, 2020.
View at: Publisher Site | Google Scholar
H. Arksey and L. O’Malley, “Scoping studies: towards a methodological framework,” International Journal of Social Research Methodology, vol. 8, no. 1, pp. 19–32, 2005.
View at: Publisher Site | Google Scholar
A. C. Tricco, E. Lillie, W. Zarin et al., “PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation,” Annals of Internal Medicine, vol. 169, no. 7, pp. 467–473, 2018.
View at: Publisher Site | Google Scholar
J. Saikarthik, “Experiencia de Aprendizaje Electrónico de Anatomía en Arabia Saudita Durante la Pandemia de COVID-19-Una Revisión Narrativa,” International Journal of Morphology, vol. 41, no. 4, pp. 1158–1165, 2023.
View at: Google Scholar
A. Lachmann, H. Xu, J. Krishnan, S. I. Berger, A. R. Mazloom, and A. Ma’ayan, “ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments,” Bioinformatics, vol. 26, no. 19, pp. 2438–2444, 2010.
View at: Publisher Site | Google Scholar
T. Ozaki, D. Wu, H. Sugimoto, H. Nagase, and A. Nakagawara, “Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage,” Cell Death and Disease, vol. 4, no. 4, 2013.
View at: Publisher Site | Google Scholar
R. C. D'Alonzo, N. Selvamurugan, G. Karsenty, and N. C. Partridge, “Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation,” Journal of Biological Chemistry, vol. 277, no. 1, pp. 816–822, 2002.
View at: Publisher Site | Google Scholar
S. H. Lee, X. Che, J. H. Jeong et al., “Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes,” Journal of Biological Chemistry, vol. 287, no. 18, pp. 14760–14771, 2012.
View at: Publisher Site | Google Scholar
J. M. Argilés, S. Busquets, B. Stemmler, and F. J. López-Soriano, “Cancer cachexia: understanding the molecular basis,” Nature Reviews Cancer, vol. 14, no. 11, pp. 754–762, 2014.
View at: Publisher Site | Google Scholar
Y. Ma, J. Gao, and H. Guo, “miR-23a-3p regulates Runx2 to inhibit the proliferation and metastasis of oral squamous cell carcinoma,” Journal of Oncology, vol. 2022, Article ID 8719542, 11 pages, 2022.
View at: Publisher Site | Google Scholar
Y. Y. Wang, Y. K. Chen, S. Lo et al., “MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner,” Oncogene, vol. 40, no. 20, pp. 3510–3532, 2021.
View at: Publisher Site | Google Scholar
S. Khanal, J. D. Strickley, T. Ha et al., “Human papillomavirus-positivity is associated with EREG down-regulation and promoter hypermethylation in head and neck squamous cell carcinoma,” Experimental and Molecular Pathology, vol. 117, Article ID 104549, 2020.
View at: Publisher Site | Google Scholar
W. M. Chang, Y. F. Lin, C. Y. Su et al., “Parathyroid hormone-like hormone is a poor prognosis marker of head and neck cancer and promotes cell growth via RUNX2 regulation,” Scientific Reports, vol. 7, no. 1, Article ID 41131, 2017.
View at: Publisher Site | Google Scholar
W. M. Chang, Y. F. Lin, C. Y. Su et al., “Dysregulation of RUNX2/activin-A Axis upon miR-376c downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma,” Cancer Research, vol. 76, no. 24, pp. 7140–7150, 2016.
View at: Publisher Site | Google Scholar
J. Quan, C. Zhou, N. W. Johnson, G. Francis, J. E. Dahlstrom, and J. Gao, “Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma,” Pathology, vol. 44, no. 3, pp. 221–227, 2012.
View at: Publisher Site | Google Scholar
L. Wen, J. Li, H. Guo et al., “Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients,” Cell Research, vol. 25, no. 11, pp. 1250–1264, 2015.
View at: Publisher Site | Google Scholar
A. Wessely, A. Waltera, T. E. Reichert, S. Stöckl, S. Grässel, and R. J. Bauer, “Induction of ALP and MMP9 activity facilitates invasive behavior in heterogeneous human BMSC and HNSCC 3D spheroids,” The Federation of American Societies for Experimental Biology Journal, vol. 33, no. 11, pp. 11884–11893, 2019.
View at: Publisher Site | Google Scholar
A. Alblihy, R. Ali, M. Algethami et al., “Selective killing of BRCA2-deficient ovarian cancer cells via MRE11 blockade,” International Journal of Molecular Sciences, vol. 24, no. 13, Article ID 10966, 2023.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2024 Khalid A. AL-Hamad. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

111

Downloads

98

Citations